

1 **Preliminary evidence from a multicenter prospective observational**
2 **study of the safety and efficacy of chloroquine for the treatment of**
3 **COVID-19**

4 Mingxing Huang^{1*}, Man Li^{2*}, Fei Xiao^{1,2*}, Jiabi Liang^{3*}, Pengfei Pang^{2,4*},
5 Tiantian Tang^{5*}, Shaoxuan Liu⁶, Binghui Chen⁷, Jingxian Shu³, Yingying You⁸,
6 Yang Li², Meiwen Tang⁹, Jianhui Zhou¹⁰, Guanmin Jiang¹⁰, Jingfen Xiang¹¹,
7 Wenxin Hong¹², Songmei He¹³, Zhaoqin Wang¹⁴, Jianhua Feng¹⁵, Changqing
8 Lin¹⁶, Yinong Ye¹⁷, Zhilong Wu¹⁸, Yaocai Li¹⁹, Bei Zhong²⁰, Ruilin Sun²¹,
9 Zhongsi Hong¹, Jing Liu²², Huili Chen¹, Xiaohua Wang²³, Zhonghe Li²⁴,
10 Duanqing Pei^{25,26†}, Lin Tian^{3†}, Jinyu Xia^{1†}, Shanping Jiang^{5†}, Nanshan
11 Zhong^{27†}, Hong Shan^{1,2†}

12

- 13 1. Department of Infectious Diseases, The Fifth Affiliated Hospital, Sun
14 Yat-sen University, Zhuhai, Guangdong Province, China
15 2. Guangdong Provincial Key Laboratory of Biomedical Imaging and
16 Guangdong Provincial Engineering Research Center of Molecular
17 Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai,
18 Guangdong Province, China
19 3. Department of Pharmacy, The Fifth Affiliated Hospital, Sun Yat-sen
20 University, Zhuhai, Guangdong Province, China
21 4. Interventional Medical Center, Guangdong Provincial Key
22 Laboratory of Biomedical Imaging, Zhuhai, Guangdong Province,
23 China
24 5. Department of Respiratory and Critical Care Medicine, Sun Yat-sen
25 Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong
26 Province, China
27 6. Clinical Research Center Office, The Fifth Affiliated Hospital, Sun
28 Yat-sen University, Zhuhai, Guangdong Province, China
29 7. Department of Radiology, The Fifth Affiliated Hospital, Sun Yat-sen
30 University, Zhuhai, Guangdong Province, China

- 31 8. Department of Oral and Maxillofacial Surgery, The Fifth Affiliated
32 Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province,
33 China
- 34 9. Department of Hematology, The Fifth Affiliated Hospital, Sun Yat-
35 sen University, Zhuhai, Guangdong Province, China
- 36 10. Department of Clinical Laboratory, The Fifth Affiliated Hospital, Sun
37 Yat-sen University, Zhuhai, Guangdong Province, China
- 38 11. Department of Emergency, Wuhan East West Lake Mobile Cabin
39 Hospitals, Wuhan, Hubei Province, China
- 40 12. Department of Infectious Diseases, Guangzhou Eighth People's
41 Hospital, Guangzhou Province, Guangdong Province, China
- 42 13. Department of Infectious Diseases, Dongguan Ninth People's
43 Hospital, Dongguan, Guangdong Province, China
- 44 14. Department of Infectious Diseases, Shenzhen Third People's
45 Hospital, Shenzhen, Guangdong Province, China
- 46 15. Department of Infectious Diseases, Zhongshan Second People's
47 Hospital, Zhongshan, Guangdong Province, China
- 48 16. Department of Respiratory and Critical Care Medicine, Huizhou
49 Central People's Hospital, Huizhou, Guangdong Province, China
- 50 17. Department of Infectious Diseases, Foshan First people's Hospital,
51 Foshan, Guangdong Province, China
- 52 18. Department of Respiratory and Critical Care Medicine, Foshan
53 Fourth People's Hospital, Foshan, Guangdong Province, China
- 54 19. Department of Infectious Diseases, Maoming People's Hospital,
55 Maoming, Guangdong Province, China
- 56 20. Department of Infectious Diseases, Qingyuan People's Hospital,
57 Qingyuan, Guangdong Province, China
- 58 21. Department of Respiratory and Critical Care Medicine, Guangdong
59 Second People's Hospital, Guangzhou, Guangdong Province, China
- 60 22. Department of Respiratory and Critical Care Medicine, The Fifth
61 Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong
62 Province, China
- 63 23. Intensive Care Unit, The Fifth Affiliated Hospital, Sun Yat-sen
64 University, Zhuhai, Guangdong Province, China

65 24. Department of Nephropathy, The Fifth Affiliated Hospital, Sun Yat-
66 sen University, Zhuhai, Guangdong Province, China

67 25. Guangzhou Regenerative Medicine and Health Guangdong
68 Laboratory, Guangzhou, Guangdong Province, China

69 26. Guangzhou Institutes of Biomedicine and Health, Chinese Academy
70 of Sciences, Guangzhou, Guangdong Province, China

71 27. State Key Laboratory of Respiratory Diseases, The First Affiliated
72 Hospital of Guangzhou Medical University, Guangzhou, Guangdong
73 Province, China.

74

75 * These authors contributed equally.

76 † These are the co-corresponding authors.

77 **Abstract**

78 **Background** Effective therapies are urgently needed for the SARS-CoV-2
79 pandemic. Chloroquine has been proved to have antiviral effect against
80 coronavirus in vitro. In this study, we aimed to assess the efficacy and safety
81 of chloroquine with different doses in COVID-19.

82 **Method** In this multicenter prospective observational study, we enrolled
83 patients older than 18 years old with confirmed SARS-CoV-2 infection
84 excluding critical cases from 12 hospitals in Guangdong and Hubei Provinces.
85 Eligible patients received chloroquine phosphate 500mg, orally, once (half
86 dose) or twice (full dose) daily. Patients treated with non-chloroquine therapy
87 were included as historical controls. The primary endpoint is the time to
88 undetectable viral RNA. Secondary outcomes include the proportion of
89 patients with undetectable viral RNA by day 10 and 14, hospitalization time,
90 duration of fever, and adverse events.

91 **Results** A total of 197 patients completed chloroquine treatment, and 176
92 patients were included as historical controls. The median time to achieve an
93 undetectable viral RNA was shorter in chloroquine than in non-chloroquine
94 (absolute difference in medians -6.0 days; 95% CI -6.0 to -4.0). The duration
95 of fever is shorter in chloroquine (geometric mean ratio 0.6; 95% CI 0.5 to 0.8).
96 No serious adverse events were observed in the chloroquine group. Patients
97 treated with half dose experienced lower rate of adverse events than with full
98 dose.

99 **Conclusions** Although randomised trials are needed for further evaluation, this
100 study provides evidence for safety and efficacy of chloroquine in COVID-19
101 and suggests that chloroquine can be a cost-effective therapy for combating

102 the COVID-19 pandemic.

103 **Introduction**

104 The coronavirus disease 2019 (COVID-19) emerged in late 2019,
105 originating from Wuhan China^{1,2}. The responsible virus, severe acute
106 respiratory syndrome coronavirus 2 (SARS-CoV-2), belongs to a distinct clade
107 from the human severe acute respiratory syndrome CoV (SARS-CoV) and
108 Middle East respiratory syndrome CoV (MERS-CoV)³. It has become a global
109 pandemic, affecting over 100 countries with more than 240,000 confirmed
110 cases and over 10,000 deaths globally as of March 20, 2020, calling for an
111 urgent demand of effective treatment.

112 Chloroquine has been proved effective in vitro to inhibit the replication
113 of SARS-CoV⁴, HCoV-229E⁵, and the newly discovered SARS-CoV-2^{6,7}. To
114 evaluate the efficacy and safety of chloroquine for COVID-19, we previously
115 conducted a single-arm pilot clinical study with 10 patients (Huang et al.
116 *Journal of Molecular Cell Biology*, in press). Encouragingly, all patients
117 achieved undetectable level of viral RNA within 14 days without serious
118 adverse events. These results led us to conduct a multicenter prospective
119 observational study in adult patients with COVID-19 to assess the efficacy
120 and safety of chloroquine for COVID-19.

121

122 **Result**

123 **Patients**

124 Of the 233 enrolled patients for chloroquine, 197 (84.5%) completed
125 treatment and were included in the final analysis (**Figure 1, study flowchart;**
126 **Supplementary Table 1**). Of the 182 patients collected as historical controls,
127 176 (96.7%) were included in the final analysis. Their baseline demographic
128 and clinical features are listed in **Table 1**. The median age of patients were 43

129 years (inter-quartile range [IQR], 33 to 55 years) in the chloroquine group and
130 47.5 years (IQR, 35.8 to 56 years) in the non-chloroquine group. Across the
131 two treatment groups, the majority patients were classified as moderate cases
132 (93.4% in chloroquine; 89.2% in non-chloroquine)⁸. Chloroquine was added
133 into China's Diagnosis and Treatment Guidelines of COVID-19 later than the
134 other therapies used in the non-chloroquine group. Therefore, we observed
135 longer interval time between symptom onset and treatment initiation in
136 chloroquine versus non-chloroquine (absolute difference 4 days; 95% CI 2 to
137 6 days; $P < 0.0001$). In addition, due to the rapid rise of patients in Wuhan
138 and established mobile hospital in early February, the interval time between
139 symptom onset and treatment initiation in Wuhan (median 17 days, IQR 10.5
140 to 21 days) is longer than that in Guangdong Province (median 5 days, IQR 3
141 to 10 days; **Table 1**). In the subgroup of patients from the Fifth Affiliated
142 Hospital of Sun Yat-sen University (SYSU5), we obtained and evaluated the
143 viral load at baseline between chloroquine (N=21) and non-chloroquine (N=8)
144 group and did not observe statistically significant difference (absolute
145 difference in medians = 2.93, 95% CI -0.8 to 6.6, $p = 0.09$).

146 **Outcomes**

147 In the analysis of the full study population, patients in the chloroquine
148 group have an accelerated time to undetectable viral RNA from that of
149 patients in the non-chloroquine group (absolute difference in medians -5.4
150 days; 95% CI -6 to -4; $P < 0.0001$; **Figure 2**). Secondly, by day 10 and day 14
151 since treatment initiation, higher proportion of patients had undetectable viral
152 RNA in the chloroquine group (91.4% and 95.9% respectively; **Table 2**)
153 comparing to the non-chloroquine group (57.4% and 79.6% respectively;

154 **Table 2**). In the aspect of clinical manifestations, we found that the duration of
155 fevers is shorter in chloroquine versus non-chloroquine among patients
156 experienced fever symptom (geometric mean ratio 0.6; 95% CI 0.5 to 0.8; $P =$
157 0.0029; **Supplementary Figure S1**). To note, the antipyretic effects of
158 chloroquine may have also contributed to this result. We observed no
159 difference in the length of hospital stay (**Supplementary Figure S2**). No
160 patient died or admitted to ICU either in the chloroquine group or in the non-
161 chloroquine group. There are 1 patient in the chloroquine group experienced
162 aggravated symptoms from moderate to severe, while 9 patients in the non-
163 chloroquine group have the same aggravated experience. All of the 10
164 patients eventually were tested negative for the viral RNA within the study
165 period.

166 Due to the significant difference observed in clinical classification between
167 chloroquine and non-chloroquine group at baseline, we further analyzed the
168 primary and secondary outcomes in patients with moderate symptoms only.
169 The number of patients in mild or severe subgroup were too few to compare.
170 The benefit of chloroquine in viral suppression is consistent with the full
171 analysis, except for non-significant difference observed for the proportion of
172 patients with undetectable viral RNA by day 14 (**Supplemental Table 2**).

173 In post hoc analysis, we examined the effect of chloroquine on the time to
174 undetectable viral RNA stratified by different doses, types of clinical
175 manifestation, the interaction between province and time from symptom onset
176 to treatment initiation, and a representative center (**Figure 3**). Chloroquine
177 showed beneficial effect in all stratum. However, the beneficial effect is not
178 statistically significant in patients with severe COVID-19 symptoms, patients

179 from Guangdong Province treated later than 14 days after symptom onset, or
180 patients from SYSU5.

181 In order to assess the effect of chloroquine in more detailed clinical
182 improvement outcomes in post hoc analysis, we collected detailed clinical
183 data in patients from SYSU5, including the improvement of chest CT, the
184 monitoring of serum chloroquine concentration, and the reappearance of
185 positive viral RNA detection after hospital discharge. In this subgroup of
186 patients, the interval time between symptom onset and treatment initiation
187 were comparable. The medians are 7 days in chloroquine group (N=50) and 6
188 days in non-chloroquine group (N=21) (absolute difference in medians 1 day;
189 95% CI -3 to 4 days; $P = 0.99$; **Supplemental Table 3**). We did not find
190 statistically significant difference in the time to undetectable viral RNA
191 between the two groups (absolute difference in medians -3.5 days; 95% CI -6
192 to 1 days). The chloroquine group have higher percentage of patients with
193 improved chest CT by day 10 (absolute difference in proportions 9.7; 95% CI -
194 16.0 to 35.6) and day 14 (absolute difference in proportions 6.3; 95% CI -22.2
195 to 32.0) than the non-chloroquine group but the difference is not statistically
196 significant (**Supplemental Table 3**). This could be due to the small sample
197 size or the delayed chest CT absorption⁹. We did not observe beneficial effect
198 of chloroquine in the length of hospital stay and the duration of oxygen
199 support (**Supplemental Table 3**). Unprecedentedly, we observed 3 cases of so
200 called “re-positive” patients in the chloroquine group. They were identified with
201 negative viral RNA test from respiratory tract samples but positive viral RNA
202 test from fecal samples within 7 days following hospital discharge. No such

203 observation in the non-chloroquine group. Investigation is underway to
204 examine whether it is due to re-infection or other factors.

205 Among the 12 hospitals, one hospital explored different dosage of
206 chloroquine, as 500 mg once daily, which is half of the protocol dosage. We
207 compared the primary and secondary outcomes in patients from this subgroup
208 (N=29) with the non-chloroquine group in Guangdong Province. The results
209 mainly showed that chloroquine has benefit effect on the time to undetectable
210 viral RNA (absolute difference in medians -5 days; 95% CI -6.0 to -4.0 days)
211 and the proportion of patients with undetectable viral RNA by day 10 is higher
212 in chloroquine group (absolute difference in proportions 32.7; 95% CI 23.9 to
213 42.1). The duration of fever was also shorter than those in the non-
214 chloroquine group (geometric mean ratio 0.8; 95% CI 0.5 to 0.9)
215 **(Supplemental Table 4).**

216

217 **Safety**

218 A total of 53 patients (26.9%) in the chloroquine group and 57 (32.4%) in
219 the non-chloroquine group reported adverse events during study period
220 **(Table 3)**. Gastrointestinal events including vomiting, abdominal distension,
221 nausea, decreased appetite, thirst were more common in chloroquine than in
222 the non-chloroquine group. The percentage of patients with neurological
223 adverse events, including dizziness and sleep order, were higher in the
224 chloroquine than in the non-chloroquine group. In addition, anxiety was
225 observed more frequently in chloroquine than in the non-chloroquine group.
226 We observed fewer adverse events in patients with half dose of chloroquine
227 than full dose (absolute difference in proportions -40; 95% CI -60 to -29).

228 Chloroquine phosphate has a long half-life (20-60 days)¹⁰⁻¹² and its
229 mean residence time is approximately 20 days¹⁰. It may have cumulative
230 effect¹³. In order to determine whether chloroquine has a cumulative effect in
231 the short-term treatment with COVID-19, we measured the serum
232 concentration of chloroquine in patients from SYSU5 during and off the
233 treatment. The results showed that the mean of serum concentration of
234 chloroquine gradually rising, with the highest reaching 1.80(±0.49) µmol/L
235 during medication and reduced to 0.13(±0.08) µmol/L within 28±1 days off
236 chloroquine (**Supplemental Figure 3**).

237

238 **DISCUSSION**

239 In this study, we found that patients in the chloroquine group experienced
240 significantly faster and higher rate of viral suppression comparing to the non-
241 chloroquine group in both the full analysis and the post hoc stratified analysis.
242 Even when the dose reduced to half, the benefit of chloroquine still remained
243 (**Figure 3**). These findings indicate that chloroquine could be effective in
244 treating patients with COVID-19. To our knowledge, this is the first and largest
245 clinical study on chloroquine phosphate for treating COVID-19 to date.

246 We recognize that our study has several limitations. This study was
247 carried out under the COVID-19 public health emergency. Due to the limited
248 medical capacity and urgent clinical situation, we were unable to conduct a
249 standard randomised controlled study to formally evaluate efficacy and safety
250 of chloroquine versus placebo. As an observational study, we have to note
251 that several factors may influence the interpretation of the result. It is
252 reasonable to suspect that the dramatic improvement in the primary outcome

253 in chloroquine could be due to the later treatment initiation since symptom
254 onset. Firstly, gaining experience in treatment management and attenuation of
255 the virus during the course of the epidemic could contribute to the improved
256 outcomes. Secondly, we cannot rule out the possibility that among those with
257 longer interval time between symptom onset and treatment, some may
258 already have been on the course of recovery. Nevertheless, post hoc analysis
259 dividing subgroups according to the interval time did not change the
260 conclusion that the chloroquine group had a better outcome than the non-
261 chloroquine group. Notably, some of the strata were incomparable due to
262 small sample size. Thirdly, although it is impossible to dissect the influence
263 from other antiviral therapies used before chloroquine, it is a plausible
264 assumption that chloroquine is the first antiviral therapy used in the group of
265 patients treated within 3 days since symptom onset. In this stratum,
266 chloroquine still benefits patients with faster viral suppression (**Figure 3**).
267 Lastly, due to the differences in personnel and technical equipment of among
268 all hospitals, we could not fully collect clinical and laboratory data of all
269 patients. However, detailed clinical data were obtained from the chloroquine
270 patients enrolled from SYSU5, enabling advanced analysis of clinical
271 outcomes and pharmacokinetics.

272 As of this time, there are more than 20 trials ongoing for evaluating the
273 efficacy and safety of chloroquine or hydroxychloroquine in treating COVID-19.
274 Magagnoli et al. recently published a retrospective study indicating that the
275 use of hydroxychloroquine with or without azithromycin does not reduced the
276 risk of mechanical ventilation in United States veterans hospitalized with
277 COVID-19¹⁴. Comparing with this study, our study population included both

278 genders, was much younger, has fewer patients with severe symptoms that
279 requires ventilation. Therefore, prospective randomised trials are needed to
280 see if the results can be replicated.

281 Till now, the mechanism of chloroquine's effect against SARS-CoV-2
282 remained unelucidated. Clatherin-mediated endocytosis is required for entry
283 of coronavirus into host cells and meanwhile autophagy involves in viral
284 replication¹⁵. Chloroquine inhibits clatherin-mediated endocytosis by
285 suppressing acidification of endosomes, and autophagy by raising its
286 lysosomal PH and blocking fusion of autophagosome with lysosome and
287 lysosomal protein degradation¹⁶. A recent study has shown that the
288 development of COVID-19 disturbed metabolic patterns, which aligned with
289 the progress and severity of COVID-19 (Wu et al. National Science Review
290 2020, in press). Chloroquine has a favorable effect on glucose and lipid
291 metabolism¹⁷. Therefore, chloroquine may exert its antiviral effect against
292 SARS-CoV-2 by inhibiting endocytosis and autophagy, and stabilizing glucose
293 and lipid metabolism.

294 The adverse reactions of chloroquine drugs are of great concern to the
295 community. Although it is an old anti-malarial drug, its safety in treating
296 COVID-19 patients is still unknown. In the present study, we did not observe
297 serious adverse events in patients with chloroquine. All adverse events
298 observed during the study period are known side-effects for chloroquine
299 (**Table 3**). The main adverse events were symptoms in gastrointestinal and
300 neuropsychiatric systems. Chloroquine is known for its side effects in
301 cardiovascular system. In the chloroquine group, we did not find significantly
302 higher rate of adverse events in patients older than 65 or with pre-existing

303 conditions (**Supplement Table 5**). Adverse event appeared in 1 out of 29
304 patients (3.5%) with half dose while in 52 out 168 patients (31.0%) with full
305 dose, indicating that the half dose group has lower adverse event rate
306 (absolute rate difference -27.5; 95% CI -45.0 to -19.2). Although previous
307 studies suggested that chloroquine may have cumulative effect^{11,18,19}, we did
308 not observe cumulative effects among 50 patients from SYSU5 by monitoring
309 the serum concentration of chloroquine for up to 28 days after treatment
310 completion. Future studies are needed to determine the optimal dosing for
311 treating COVID-19 and the cumulative effect of chloroquine in tissues and
312 organs. Severe cases are underrepresented in the present study, and thus
313 should be focused in the future studies to evaluate the efficacy and safety
314 profile in this population. In addition, it will be important to study the
315 prophylaxical use of chloroquine in areas with high rate of COVID-19 or in
316 health professionals working with COVID-19 patients.

317 In conclusion, our preliminary evidence showed that chloroquine has the
318 potential to shorten the time to SARS-CoV-2 viral suppression and duration of
319 fever, even with reduced dose. Further randomised studies are needed to
320 determine the optimal dose, to assess its benefit for both severe cases and to
321 assess its benefit in settings other than secondary care. Considering that
322 there is no better option at present, chloroquine could be a viable option to
323 combat the coronavirus pandemic under proper management.

324

325 **METHODS**

326 **Study Design and participants**

327 This study was a multicenter prospective observational study
328 conducted from February 7 through March 8, 2020 at 11 hospitals in

329 Guangdong Province and 1 mobile cabin hospital in Wuhan, Hubei Province,
330 China. The study protocol was approved by the ethics committee of Fifth
331 Affiliated Hospital of Sun Yat-sen University (SYSU5), located in Zhuhai,
332 Guangdong Province, and registered at Chinese Clinical Trial Registry
333 (ChiCTR2000029609). We did this study in accordance with the principles of
334 the Declaration of Helsinki and Good Clinical Practice. Written informed
335 consent was obtained from all patients or their legal guardians. During the
336 study period, each hospital had various choices of antiviral regimen, and the
337 sample size of Lopinavir/Ritonavir (the historical control group in the original
338 protocol) for single-use were underpowered. Thus, we updated the inclusion
339 criteria of the historical control group as patients receiving non-chloroquine
340 treatment.

341 Eligible patients were aged 18 years or older with confirmed SARS-
342 CoV-2 infection, tested by the local Center for Disease Control (CDC) or by a
343 designated diagnostic laboratory, using reverse-transcriptase-polymerase-
344 chain-reaction (RT-PCR) assay (Shanghai ZJ Bio-Tech Co Ltd) for SARS-
345 CoV-2 in a respiratory tract sample. Patients were ineligible if he/she met any
346 of the following criteria: pregnant women, with known allergies to 4-
347 aminoquinoline compounds, blood system diseases, chronic liver or kidney
348 diseases in end-stage, arrhythmia or second/third degree heart block, with
349 known to have retinopathy, hypoacusis or hearing loss, mental disease,
350 glucose-6-phosphate dehydrogenase (G6PD) deficiency, had received
351 digitalis drugs within the 7 days preceding enrollment, or is classified as
352 critical case according to China's Novel Coronavirus Pneumonia Diagnosis
353 and Treatment Plan (4th Edition). Enrolled patients received 500mg

354 chloroquine Phosphate (equivalent of 300 mg chloroquine base, Shanghai
355 Xinyi Pharmaceutical Co., Ltd) orally, once/twice-daily with no other antiviral
356 therapies. The criteria of stopping chloroquine was defined as undetectable
357 viral RNA for two consecutive respiratory tract samples. The duration of
358 medication in chloroquine group is no more than 10 days. Patients in the
359 historical control group were treated according to China's Novel Coronavirus
360 Pneumonia Diagnosis and Treatment Plan (details described in
361 **Supplemental Table 6**).

362

363 **Outcome and measurements**

364 The primary outcome is the time from treatment initiation to
365 undetectable viral RNA for two consecutive respiratory tract samples. The
366 secondary outcomes include the proportion of patients with undetectable viral
367 RNA by day 10 and 14, duration of fevers, time in hospital, and adverse
368 events. The detailed definition of outcomes is described in **Supplementary**
369 **Methods**. Respiratory tract sample was collected from patients daily
370 to conduct RT-PCR assay for SARS-CoV-2 infection. The epidemiological
371 characteristics, clinical symptoms and signs, adverse reactions/events were
372 collected with data collection forms. The outcomes, clinical characteristics,
373 laboratory findings, chest computed tomographic (CT) scans were recorded
374 on case record forms and then double-entered into an electronic database
375 and validated by trial staff. After hospital discharge, patients were followed up
376 once weekly. Patients with "re-positive" viral RNA detection within one week
377 after hospital discharge are defined as having either 2 consecutive RT-PCR
378 positive result from either respiratory tract sample or fecal specimen. In the

379 subgroup of patients in SYSU5, all CT images were reviewed by two
380 fellowship-trained cardio-thoracic radiologists by using a viewing console.
381 Images were reviewed independently, and final decisions were reached by
382 consensus ⁹.

383 To fully assess the safety of chloroquine, we monitor the serum
384 concentration of chloroquine at the day 1, 3, 5, 7, 10 during drug
385 administration and day 1 to 7, and day 14, day 21 after treatment completion
386 in a subgroup of samples enrolled from SYSU5 (N=50). Details about the
387 measurement of serum concentration of chloroquine are described in

388 **Supplemental Methods.**

389 **Statistical Analysis**

390 The original plan was to compare the efficacy between three groups,
391 chloroquine only, Lopinavir/Ritonavir only, and chloroquine plus
392 Lopinavir/Ritonavir. At the beginning of the outbreak, different therapies were
393 proposed and tested for the treatment of COVID-19. Therefore, it is
394 challenging to find sufficient patients with unified treatment across all centers.
395 The epidemic in Guangdong had been brought under control rapidly during
396 the study making it difficult to recruit patients as planned. The history of
397 changes to the protocol is listed in **Supplemental Table 7**. Thus, a decision
398 was made to focus on recruiting chloroquine only and compare the efficacy
399 with historical controls. The current sample size was based on feasibility
400 within the fixed trial recruitment window and was felt would provide sufficient
401 precision for the estimation of plausible effects. With right-censoring in time-
402 to-event variables, generalized Wilcoxon test was used to compare the
403 difference in medians and the 95% confidence intervals were calculated by

404 bootstrapping²⁰. For binary outcomes, Wilson test was implemented to
405 calculate the difference in proportions and 95% confidence intervals. As this
406 was an observational study, imbalance in the baseline characteristics of the
407 two groups was expected. To adjust for this imbalance, we performed post
408 hoc analyses within various subgroups by two dosage options, by clinical
409 manifestation, by the interaction of province and the interval time between
410 symptom onset and treatment initiation (≤ 3 days; 3~7 days; 7~14 days; > 14
411 days), and by center. For all comparative analyses, $P < 0.05$ was considered
412 statistically significant. No allowance for multiplicity. All P values are two tailed.
413 All statistical analyses were performed in R, version 3.6.1 (R Foundation for
414 Statistical Computing)²¹.

415 **Role of the funding source**

416 The sponsor of the study had no role in study design, data collection, data
417 analysis, data interpretation, or writing of the report. The corresponding author
418 had full access to all the data and had final responsibility for the decision to
419 submit for publication.

420 **Contributors**

421 S.H, N.Z, S.J. J.X. L.T and D.P. had the idea for and designed the study and had full
422 access to all data in the study and take responsibility for the integrity of the data and
423 the accuracy of the data analysis. M.L, F.X, Y.L., M.H, J.L, P.P and T.T contributed
424 to writing of the report. M.L, F.X, M.H, Y.L., J.L and P.P contributed to critical
425 revision of the report. M.L contributed to the statistical analysis. All authors
426 contributed to data acquisition, data analysis, or data interpretation, and reviewed
427 and approved the final version.

428

429 **Declaration of interest**

430 All authors declare no competing interests.

431

432 **Data sharing**

433 The data that support the findings of this study are available from the corresponding
434 author on reasonable request. Participant data without names and identifiers will be
435 made available after approval from the corresponding author and Ministry of science
436 and technology and Health Committee in Guangdong province. After publication of
437 study findings, the data will be available for others to request. The research team will
438 provide an email address for communication once the data are approved to be
439 shared with others. The proposal with detailed description of study objectives and
440 statistical analysis plan will be needed for evaluation of the reasonability to request
441 for our data. The corresponding author and Ministry of science and technology and
442 Health Committee in Guangdong province will make a decision based on these
443 materials. Additional materials may also be required during the process.

444

445 **Acknowledgements**

446 We thank all patients who participated in this study and their families. We also thank
447 all the health care workers on the front lines of the COVID-19 pandemic. This work
448 was supported in part by National key Research and Development (R&D plan "public
449 security risk prevention and control and emergency technical equipment": Novel
450 coronavirus infection pneumonia diagnosis and control key technology research
451 (2020YFC082400), Guangdong Research and Development (R&D) Program in Key
452 Areas: Guangdong Scientific and Technological Research Special fund for
453 Prevention and Treatment of COVID-19, Special fund for emergency research on

454 SARS-CoV-2 from the Guangzhou Regenerative Medicine and Health Guangdong
455 Laboratory, Cultivation Project of "Three Major Scientific Research Projects" of Sun
456 Yat-sen University in 2020, Emergency Project of New Coronavirus Prevention and
457 Control Science and Technology of Sun Yat-sen University, and Zhuhai 2020 "novel
458 coronavirus infection control" emergency technology tackling key issues. We thank
459 all the participants in this study. We acknowledge all health-care workers who
460 provided care for the patients at the 12 hospitals. We thank Jiaxing Taimei Medical
461 Technology Co., Ltd for Electronic Data Capture service.

462 **Table 1. Baseline characteristics in chloroquine and non-chloroquine among**
 463 **people with COVID-19.**
 464

	chloroquine (N=197)	Non-chloroquine (N=176)
Guangdong, N (%)	118 (60)	96 (54)
Hubei, N (%)	79 (40)	80 (46)
Age, mean (SD)	43.8 (13.1)	45.6 (13.5)
Age ≤ 65	190 (96)	171 (97)
Age > 65	7 (4)	5 (3)
Female sex, N (%)	101 (51)	97 (55)
Clinical manifestation [†] , N (%)		
Mild	9 (5)	5 (3)
Moderate	184 (93)	157 (89)
Severe	4 (2)	14 (8)
Comorbidities, N (%) [*]		
Hypertension	13 (17)	11 (17)
Type 2 diabetes	4 (5)	5 (8)
Interval time from symptom onset to treatment initiation, median (IQR)		
Guangdong	7 (3, 10.8)	4 (2, 7)
Hubei	19 (17, 24.5)	11 (7, 16)
Body temperature, median (IQR), °C	36.7 (36.5, 37.0)	36.6 (36.4, 37.3)
Pneumonia from chest CT, N (%) [§]	173 (89)	137 (93)

465 * The number of patients with valid record of comorbidities are 78 in chloroquine
 466 group and 66 in non-chloroquine group

467 § The number of patients with valid record of chest CT image are 194 in chloroquine
 468 group and 148 in non-chloroquine group.

469 † clinical manifestation type definitions: 1) Mild, mild clinical symptoms with no signs
 470 of pneumonia on chest radiological imaging; 2) Moderate, fever, respiratory
 471 symptoms, imaging with pneumonia changes; 3) Severe, meet any of the following
 472 criteria: shortness of breath, respiratory rate > 30 times per minute, resting stable
 473 oxygen saturation in fingertip < 93%, oxygenation index < 300, pulmonary imaging
 474 showed that the lesion progressed significantly more than 50% within 24-48 hours; 4)
 475 Critical, if any of the following occurs: respiratory failure requiring mechanical
 476 ventilation; shock, concurrent with other organ failure requires intensive care.

477 **Table 2. Outcomes in the overall population with confirmed SARS-CoV-2**
 478 **infection[§].**
 479

	chloroquine (N=197)	Non- chloroquine (N=176)	Difference (95% CI)[†]	P value
Time to undetectable viral RNA, median no. of days (IQR)	3.0 (3.0, 5.0)	9.0 (6.0, 12.0)	-6.0 (-6.0, -4.0)	< 0.0001
Patients with undetectable viral RNA by, N (%)				
Day 10	180.0 (91.0)	101.0 (57.0)	34.0 (25.6, 42.9)	< 0.0001
Day 14	189.0 (96.0)	140.0 (80.0)	16.0 (9.2, 23.3)	< 0.0001
Duration of fever*, no. of days, geometric mean (CV)	1.2 (53.5)	1.9 (110.0)	0.6 (0.5, 0.8)	0.0029
Length of hospital stay, median no. of days (IQR)	19.0 (16.0, 23.0)	20.0 (15.8, 24.0)	-1.0 (-3.0, 0.0)	0.25

480 Abbreviations: CI, confidence interval; IQR, inter-quartile range; CV, coefficient of
 481 variation.

482 [§] Definitions of outcomes are listed in Supplemental Methods.

483 [†] 95% CI for continuous variables are calculated by bootstrapping. 95% CI for binary
 484 variables are calculated with Wilson method. The difference for duration of fever is
 485 geometric mean ratio of chloroquine group to non-chloroquine group. The
 486 differences for all other variables are the absolute difference between chloroquine
 487 group and non-chloroquine group.

488 * The number of patients had at least one day of fever is 42 and 51 in the
 489 chloroquine and non-chloroquine group respectively.


490 **Table 3. Summary of adverse events[§].**

491

Event, N (%)	chloroquine (N=197)	Non-chloroquine (N=176)
Any adverse event	53 (26.9)	57 (32.4)
Gastrointestinal		
Vomiting	9 (4.6)	2 (1.1)
Abdominal distension	2 (1.0)	1 (0.6)
Abdominal pain	2 (1.0)	2 (1.1)
Nausea	18 (9.1)	7 (4.0)
Diarrhea	6 (3.0)	11 (6.3)
Decreased appetite	7 (3.6)	0 (0)
Thirst	4 (2.0)	0 (0)
Acid reflux	1 (0.5)	0 (0)
Belching	1 (0.5)	0 (0)
Neurological		
Dizziness	20 (10.2)	4 (2.3)
Headache	3 (1.5)	3 (1.7)
Sleep disorder	10 (5.1)	1 (0.6)
Psychological		
Anxiety	6 (3.0)	0 (0)
Depression	1 (0.5)	0 (0)
Delirious	1 (0.5)	1 (0.6)
Dysphoria	1 (0.5)	0 (0)
Emotional Unstable	1 (0.5)	0 (0)
Cardiovascular		
Pain under xiphoid	1 (0.5)	0 (0)
Chest tightness	2 (1.0)	6 (3.4)
Ventricular premature beat	0 (0)	1 (0.6)
Other		
Hand shaking/numbness	2 (1.0)	0 (0)
Muscle soreness	0 (0)	4 (2.3)
Blurred vision	3 (1.5)	0 (0)
Rash	1 (0.5)	0 (0)
Weight loss	1 (0.5)	0 (0)
Fatigue / Weakness	2 (1.0)	1 (0.6)
Shortness of breath	1 (0.5)	3 (1.7)
Unsteady gait	1 (0.5)	0 (0)


492 [§] Adverse events that occurred in more than 1 patient after treatment initiation during
 493 study period are shown. Some patients had more than one adverse event.

494 **Figure 1. Study flowchart.**



495


496 **Figure 2. Kaplan-Meier curve for time to undetectable viral RNA comparing**
497 **treatment groups.**
498



499

500

Figure 3. Post hoc analysis on the effect of chloroquine on time to undetectable viral RNA by stratification.



501
502

Abbreviations: GD, Guangdong; HB, Hubei.

503 95% CI are calculated by bootstrapping. The differences for all other variables are the absolute difference between chloroquine
504 group and non-chloroquine group.

References

1. Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. *J Med Virol* 2020; 92(4): 401-2.
2. Hui DS, E IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis* 2020; 91: 264-6.
3. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med* 2020; 382(8): 727-33.
4. Keyaerts E, Vijgen L, Maes P, Neyts J, Van Ranst M. In vitro inhibition of severe acute respiratory syndrome coronavirus by chloroquine. *Biochem Biophys Res Commun* 2004; 323(1): 264-8.
5. Kono M, Tatsumi K, Imai AM, Saito K, Kuriyama T, Shirasawa H. Inhibition of human coronavirus 229E infection in human epithelial lung cells (L132) by chloroquine: involvement of p38 MAPK and ERK. *Antiviral Res* 2008; 77(2): 150-2.
6. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. *Cell Res* 2020; 30(3): 269-71.
7. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. *J Crit Care* 2020.
8. Organization WH. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected: interim guidance, 28 January 2020: World Health Organization, 2020.
9. Chung M, Bernheim A, Mei X, et al. CT Imaging Features of 2019 Novel Coronavirus (2019-nCoV). *Radiology* 2020; 295(1): 202-7.
10. Gustafsson L, Lindstrom B, Grahnen A, Alvan G. Chloroquine excretion following malaria prophylaxis. *British Journal of Clinical Pharmacology* 1987; 24(2): 221-4.
11. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. *Clin Pharmacokinet* 1996; 30(4): 263-99.
12. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. *Clin Pharmacokinet* 1996; 31(4): 257-74.

13. Marks JS. Chloroquine retinopathy: is there a safe daily dose? *Ann Rheum Dis* 1982; 41(1): 52-8.
14. Magagnoli J, Narendran S, Pereira F, et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. *medRxiv* 2020: 2020.04.16.20065920.
15. Yang N, Shen HM. Targeting the Endocytic Pathway and Autophagy Process as a Novel Therapeutic Strategy in COVID-19. *Int J Biol Sci* 2020; 16(10): 1724-31.
16. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. *Science* 2004; 306(5698): 990-5.
17. Hage MP, Al-Badri MR, Azar ST. A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role. *Ther Adv Endocrinol Metab* 2014; 5(4): 77-85.
18. Augustijns P, Geusens P, Verbeke N. Chloroquine levels in blood during chronic treatment of patients with rheumatoid arthritis. *European Journal of Clinical Pharmacology* 1992; 42(4): 429-33.
19. Akpovwa H. Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity. *Cell Biochem Funct* 2016; 34(4): 191-6.
20. Keene ON. Alternatives to the hazard ratio in summarizing efficacy in time-to-event studies: an example from influenza trials. *Statistics in Medicine* 2002; 21(23): 3687-700.
21. Team RC. R: A language and environment for statistical computing. 2013.